Live market news
Stocks
MLYS

Mineralys Therapeutics, Inc. Common Stock

MLYSStockUSA

See in Charts

Latest news on MLYSranked by Oyticker for market impact

45Impact
Neutral2 Oct 2026 · 20:30 UTC · Global · Short term
Mineralys to present lorundrostat Phase 3 data at ASN Kidney Week 2026
Mineralys Therapeutics announced presentation of new Launch-HTN trial data for lorundrostat at ASN Kidney Week 2026 (Oct 21–25, Denver). The aldosterone antagonist targets hypertension and kidney disease comorbidities.
MLYSBiopharmaceuticalsSpecialty Pharma

SEC filings

What MLYS filed

All its filings

4 Nov 2026
Quarterly report (opens the document on sec.gov)10-Q
4 Nov 2026
Results announced (opens the document on sec.gov)8-K
Executive or director change
29 Oct 2026
Material agreement (opens the document on sec.gov)8-K
Agreement ended
19 Oct 2026
Executive or director change (opens the document on sec.gov)8-K
11 Aug 2026
Quarterly report (opens the document on sec.gov)10-Q
11 Aug 2026
Results announced (opens the document on sec.gov)8-K
Executive or director change
3 Jun 2026
Other event (opens the document on sec.gov)8-K
3 Jun 2026
Material agreement (opens the document on sec.gov)8-K
New debt or obligation
22 May 2026
Shareholder vote results (opens the document on sec.gov)8-K

From SEC EDGAR, the public record of what US-listed companies file. Each document opens on sec.gov.

Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.

Latest news on MLYSranked by Oyticker for market impact

Mineralys to present lorundrostat Phase 3 data at ASN Kidney Week 2026

What MLYS filed